Cargando…

Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso

We assessed anti-Vi IgG/IgA responses to typhoid conjugate vaccine (TCV) in children enrolled in a double-blind randomized controlled, phase 2 trial in Burkina Faso. Anti-Vi IgG seroconversion and anti-Vi IgA titers were higher in TCV than control recipients at 30–35 months post-vaccination. TCV ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouedraogo, Alphonse, Diarra, Amidou, Nébié, Issa, Barry, Nouhoun, Kabore, Jean Moise, Tiono, Alfred B, Datta, Shrimati, Liang, Yuanyuan, Mayo, Ifayet, Oshinsky, Jennifer J, Tracy, J Kathleen, Girmay, Tsion, Pasetti, Marcela F, Jamka, Leslie P, Neuzil, Kathleen M, Sirima, Sodiomon B, Laurens, Matthew B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533206/ https://www.ncbi.nlm.nih.gov/pubmed/37589596 http://dx.doi.org/10.1093/jpids/piad058

Ejemplares similares

Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
por: Sirima, Sodiomon B., et al.
Publicado: (2021)

Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso
por: Sirima, Sodiomon B., et al.
Publicado: (2021)

Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso
por: Diarra, Amidou, et al.
Publicado: (2012)

Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimens
por: Tiono, Alfred B, et al.
Publicado: (2009)

Transplacental Transmission of Plasmodium falciparum in a Highly Malaria Endemic Area of Burkina Faso
por: Ouédraogo, Alphonse, et al.
Publicado: (2012)

Malariometric Indices in the Context of Seasonal Malaria Chemoprevention in Children Aged 1.5 to 12 Years during the Period of High Malaria Transmission in the Suburban Area of Banfora, Burkina Faso
por: Ouattara, San M., et al.
Publicado: (2023)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
por: Morter, Richard, et al.
Publicado: (2022)

A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper
por: Laurens, Matthew B, et al.
Publicado: (2019)

Malaria Incidence in Children in South-West Burkina Faso: Comparison of Active and Passive Case Detection Methods
por: Tiono, Alfred B., et al.
Publicado: (2014)

Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso
por: Soulama, Issiaka, et al.
Publicado: (2015)

Hospital-based surveillance of severe paediatric malaria in two malaria transmission ecological zones of Burkina Faso
por: Tiono, Alfred B., et al.
Publicado: (2023)

Seasonal performance of a malaria rapid diagnosis test at community health clinics in a malaria-hyperendemic region of Burkina Faso
por: Diarra, Amidou, et al.
Publicado: (2012)

Contribution of the Rapid LAMP-Based Diagnostic Test (RLDT) to the Evaluation of Enterotoxigenic Escherichia coli (ETEC) and Shigella in Childhood Diarrhea in the Peri-Urban Area of Ouagadougou, Burkina Faso
por: Héma, Alimatou, et al.
Publicado: (2023)

Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2009)

Risk factors for Plasmodium falciparum infection in pregnant women in Burkina Faso: a community-based cross-sectional survey
por: Yaro, Jean Baptiste, et al.
Publicado: (2021)

Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2010)

Low Specificity of a Malaria Rapid Diagnostic Test During an Integrated Community Case Management Trial
por: Tiono, Alfred B., et al.
Publicado: (2013)

Erratum to: Low Specificity of a Malaria Rapid Diagnostic Test During an Integrated Community Case Management Trial
por: Tiono, Alfred B., et al.
Publicado: (2013)

Plasmodium falciparum genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso
por: Soulama, Issiaka, et al.
Publicado: (2009)

Lessons learned from the use of HRP-2 based rapid diagnostic test in community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso
por: Tiono, Alfred B, et al.
Publicado: (2014)

Different approaches for delivery of Intermittent Preventive Treatment (IPT) to pregnant women in Burkina Faso
por: Ouédraogo, Alphonse, et al.
Publicado: (2010)

A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso
por: Tiono, Alfred B, et al.
Publicado: (2013)

Plasmodium falciparum Malaria in Children Aged 0-2 Years: The Role of Foetal Haemoglobin and Maternal Antibodies to Two Asexual Malaria Vaccine Candidates (MSP3 and GLURP)
por: Kangoye, David Tiga, et al.
Publicado: (2014)

Haemoglobin variants and Plasmodium falciparum malaria in children under five years of age living in a high and seasonal malaria transmission area of Burkina Faso
por: Bougouma, Edith C, et al.
Publicado: (2012)

Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso
por: Cherif, Mariama K., et al.
Publicado: (2017)

Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children
por: Tiono, Alfred B., et al.
Publicado: (2023)

Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Burkina Faso: A Randomised, Double-Blind, Placebo-Controlled Trial
por: Konaté, Amadou T., et al.
Publicado: (2011)

Variation in haematological parameters in children less than five years of age with asymptomatic Plasmodium infection: implication for malaria field studies
por: Gansane, Adama, et al.
Publicado: (2013)

A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age
por: Ouédraogo, Alphonse, et al.
Publicado: (2013)

Malaria Morbidity in High and Seasonal Malaria Transmission Area of Burkina Faso
por: Ouédraogo, Alphonse, et al.
Publicado: (2013)

Morbidity from Malaria in Children in the Year after They Had Received Intermittent Preventive Treatment of Malaria: A Randomised Trial
por: Konaté, Amadou T., et al.
Publicado: (2011)

Feasibility and Acceptability of a Strategy Deploying Multiple First-Line Artemisinin-Based Combination Therapies for Uncomplicated Malaria in the Health District of Kaya, Burkina Faso
por: Kaboré, Jean Moïse Tanga, et al.
Publicado: (2023)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
por: Tiono, Alfred B., et al.
Publicado: (2018)

Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
por: Gonçalves, Bronner P., et al.
Publicado: (2016)

Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
por: Ouédraogo, Alphonse, et al.
Publicado: (2023)

The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
por: Sirima, Sodiomon B, et al.
Publicado: (2009)

Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso
por: Hien, Denise, et al.
Publicado: (2022)

Novel Insights Into the Protective Role of Hemoglobin S and C Against Plasmodium falciparum Parasitemia
por: Mangano, Valentina D., et al.
Publicado: (2015)

Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children
por: Bougouma, Edith Christiane, et al.
Publicado: (2022)

African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination
por: Arisue, Nobuko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6ad8kn9k0tt6s5hqair62bn1aj